PPARG and colorectal carcinoma: The study also revealed that inhibiting PPARγ with GW9662 or the PPARγ knockdown reversed the anticancer effects of HSYA on CRC cells, implicating PPARγ as a key player in HSYA’s therapeutic action [34].